Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm
Catherine M. Lockhart, Cara L. McDermott, Aaron B. Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A. DeFor, Pamala A. Pawloski
JOURNAL OF MEDICAL ECONOMICS (2023)
Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries
Krithika Rajagopalan, Nazia Rashid, Dilesh Doshi
JOURNAL OF MEDICAL ECONOMICS (2023)
Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan
Wentao Tang, Keigo Hanada, Yoshiharu Motoo, Hiroyuki Sakamaki, Takaaki Oda, Kazuyuki Furuta, Hikaru Abutani, Satoru Ito, Kiichiro Tsutani
JOURNAL OF MEDICAL ECONOMICS (2023)
Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention
Robert Cowan, Alit Stark-Inbar, Liron Rabany, Dagan Harris, Maya Vizel, Alon Ironi, Julio R. R. Vieira, Michelle Galen, Christina Treppendahl
JOURNAL OF MEDICAL ECONOMICS (2023)
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data
Heidi C. Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrome
JOURNAL OF MEDICAL ECONOMICS (2023)
Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States
Camille Rochmann, Marie Fournier, Judy Hull, Maria Perichon, Ruth Pulikottil-Jacob
JOURNAL OF MEDICAL ECONOMICS (2023)
Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal
Fabian P. Alvarez, Pierre Chevalier, Matthias Borms, Helene Bricout, Catia Marques, Anu Soininen, Tatu Sainio, Christine Petit, Caroline de Courville
JOURNAL OF MEDICAL ECONOMICS (2023)
Healthcare utilization and direct medical costs of Huntington's disease among Medicaid beneficiaries in the United States
Anisha M. Patel, Eunice Chang, Caleb Paydar, Sheila R. Reddy
JOURNAL OF MEDICAL ECONOMICS (2023)
Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England
Philip Cornford, Caolan Halpin, Jelena Sassmann, Ian Frankcom, Saran Braybrook
JOURNAL OF MEDICAL ECONOMICS (2023)
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro, Amelia Insa, Alex Martinez, Elena Fernandez, Ivana Sullivan, Andres Flores, Natalia Arrabal, David Carcedo, Alba Manzaneque
JOURNAL OF MEDICAL ECONOMICS (2023)
A systematic review of SF-6D health state valuation studies
Liang Wang, Thomas G. Poder
JOURNAL OF MEDICAL ECONOMICS (2023)
Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans
Kruti Joshi, Dominic Pilon, Aditi Shah, Christopher Holiday, Swapna Karkare, Maryia Zhdanava
JOURNAL OF MEDICAL ECONOMICS (2023)
The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study
Ryan O'Reilly, Hong Lu, Jeffrey C. C. Kwong, Allison McGeer, Teresa To, Beate Sander
JOURNAL OF MEDICAL ECONOMICS (2023)
Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis
Elliot B. Tapper, Machaon Bonafede, Jesse Fishman, Stephen Dodge, Keith Miller, Ni Zeng, Dave Lewandowski, Alina Bogdanov
JOURNAL OF MEDICAL ECONOMICS (2023)
Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain
Umakanth Vudumula, Mausam Patidar, Kapil Gudala, Elizabeth Karpf, Nicholas Adlard
JOURNAL OF MEDICAL ECONOMICS (2023)
Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States
Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, Russel Burge, Jerry Hall
JOURNAL OF MEDICAL ECONOMICS (2023)
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait
Ahmed Swidan, Gihan Hamdy Elsisi, Mohamed M. M. Ibrahim, Mohammad Aljazzar, Hossameldin Tawfik Sallam
JOURNAL OF MEDICAL ECONOMICS (2023)
Real-world clinical management of individuals with Rett syndrome: a physician survey
Damian M. May, Jeffrey L. Neul, Ambika Satija, Wendy Y. Cheng, Neema Lema, Andra Boca, Patrick Lefebvre, Jesus Eric Pina-Garza
JOURNAL OF MEDICAL ECONOMICS (2023)
Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
Junxing Chay, Joshua Yi Min Tung, Rebecca Jade Su, Edwin Jonathan Aslim, Callix Wong, Georgia Swan, Wei Jin Chua, Henry Sun Sien Ho, Eric Andrew Finkelstein
JOURNAL OF MEDICAL ECONOMICS (2023)
Healthcare costs among patients with newly diagnosed helicobacter pylori infection in the United States: a linked claims-EHR study
Shailja Shah, Katherine Cappell, Robert Sedgley, Corey Pelletier, Rinu Jacob, Machaon Bonafede, Rena Yadlapati
JOURNAL OF MEDICAL ECONOMICS (2023)